Intraductal delivery of nanocarriers for ductal carcinoma in situ treatment: a strategy to enhance localized delivery - Supplementary tables

Ductal carcinoma in situ describes the most commonly occurring, noninvasive malignant breast disease,
which could be the leading factor in invasive breast cancer. Despite remarkable advancements in
treatment options, poor specificity, low bioavailability and dose-induced toxicity of chemotherapy are
the main constraint. A unique characteristic of nanocarriers may overcome these problems. Moreover,
the intraductal route of administration serves as an alternative approach. The direct nanodrug delivery
into mammary ducts results in the accumulation of anticancer agents at targeted tissue for a prolonged
period with high permeability, significantly decreasing the tumor size and improving the survival rate.
This review focuses mainly on the intraductal delivery of nanocarriers in treating ductal carcinoma in situ,
together with potential clinical translational research.